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lorazepam by the end of second day of treatment. 
Five more patients could be declared as 
responders by the end of fourth day of treatment. 
Throughout the study period no adverse side 
effects were documented. No unpleasant 
withdrawal symptoms were reported following the 
termination of lorazepam. A large sample size 
needs to be studied to confirm these observations. 
R.CHANDRASEKARAN, Professor and Head, Department 
of Psychiatry, JIPMER, Pondicherry 
RE-EMERGENCE OF POSITIVE SYMPTOMS 
OF SCHIZOPHRENIA DURING THE COURSE 
OF TREATMENT WITH RISPERIDONE 
Sir, 
We would like to respond to the article titled 
"Re-emergence of positive symptoms of 
schizophrenia during the course of treatment with 
risperidone" (Bajaj et al.), that was published in 
the Indian Journal of Psychiatry, Vol.41/No.2/April, 
1999. It was quite interesting to note that these 
authors had observed a re-emergence of positive 
symptoms in 7 patients, out of 30 patients of 
schizophrenia treated with risperidone. We would 
like to present a brief report of a similar 
phenomenon observed in one schizophrenic 
patient undergoing treatment in the Dept. of 
Psychiatry, JIPMER Hospital, Pondicherry. 
Mr.X, a 28-yr. old unmarried male was 
hospitalized in August,1999 with an ICD-10 
diagnosis of residual schizophrenia. His illness 
had, by then, run a chronic unremitting course 
for three years, with a definite progression from 
an initial brief phase characterised by overt 
positive symptoms to the second and chronic 
stage, comprising all the typical negative 
symptoms such as avolition, apathy, social 
withdrawal, anhedonia, blunted affect and a 
gross reduction in speech output. A detailed 
cross-sectional evaluation soon after admission 
did not reveal any disorder of form of thought, 
delusions, thought-alienation phenomena or 
perceptual disturbances. Patient's baseline 
BPRS score was 24. Baseline PANSS profile was 
as follows : Positive syndrome score=11, 
negative syndrome score=46, general 
psychopathology score=39. Risperidone was 
initiated at a dose of 2 mg/day and gradually 
incraesed to a total of 8 mg/day in 2 divided 
doses. After 2 weeks of treatment with 8 mg of 
risperidone, interesting changes were observed 
in the patient's clinical profile and his scores on 
BPRS and PANSS. Total BPRS score had 
increased to 26, while the PANSS scores were 
as follows : Positive syndrome score=27, 
negative syndrome score=27, general 
psychopathology score=39. These rating scale 
scores correlated with clinically observed 
worsening of positive symptoms, especially 
conceptual disorganization and grandiosity and 
improvement in negative symptoms. 
This unusual and unexpected observation 
leads us to speculate on the rather unique 
receptor binding properties of risperidone 
(5HT2+D2 receptor antagonism), the relationship 
between the roles of serotonin and dopamine in 
schizophrenia and also the possibility of this 
phenomenon being essentially due to an 
idiosyncratic neurochemical profile in this 
particular patient. 5HT2 antagonists have been 
shown to have an antipsychotic effect, 
particularly on the negative symptom cluster 
(Bleich et a!.,1988). Research has also shown 
that risperidone is effective against both the 
positive and the negative symptoms of 
schizophrenia (Marder & Meibach,1994). 
Agarwal et al.(1998) had investigated the 
response of Indian schizophrenic patients to 
risperidone and observed a reduction in score 
in both the positive syndrome scale and the 
negative syndrome scale of PANSS. Based on 
the available literature, it is possible to explain 
the beneficial effect that risperidone has had on 
the negative symptoms of our patient. But, the 
apparent re-emergence/worsening of positive 
symptoms during treatment with risperidone is 
a strange phenomenon that seems to have no 
concrete explanation as yet. Bajaj et al.(1999) 
nave suggested that risperidone's 
antiserotonergic activity may possibly potentiate 
dopamine release at the mesolimbic region, 
counteracting the primary anti-psychotic activity, 
resulting in a re-emergence of positive 
symptoms. This is quite a plausible and 
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interesting hypothesis that needs to be clarified 
through further research, especially because 
risperidone is a highly effective anti-psychotic 
drug that has occupied an important position in 
the management of schizophrenia. 
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